All posts tagged "Co."
- / 2 years ago
FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer’s Disease with Priority Review
Biogen Inc (BIIB:NASDAQ) Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease. The application has been granted Priority Review, with a Prescription Drug User...
Get the most important news and analyses for Free.
Thank you for subscribing.
Something went wrong.